53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms

Key Takeaways Explain This Topic AI

The American Diabetes Association (ADA) diagnostic criteria require a fasting plasma glucose (FPG) >=126 mg/dL (after an 8-hour fast), a 2-hour 75g oral glucose tolerance test (OGTT) >=200 mg/dL, a glycated hemoglobin (HbA1c) >=6.5%, or a random plasma glucose >=200 mg/dL with classic hyperglycemic symptoms; asymptomatic abnormal results require repeat confirmation on a subsequent day.

Prediabetes is defined as FPG 100-125 mg/dL (impaired fasting glucose), 2-hour OGTT 140-199 mg/dL (impaired glucose tolerance), or HbA1c 5.7%-6.4%; intensive lifestyle intervention achieving 7% body weight loss and 150 minutes/week of moderate activity is first-line, with metformin strongly indicated for BMI >=35 kg/m2, age <60 years, or prior gestational diabetes mellitus.

Glycemic targets must be individualized: general non-pregnant adults target HbA1c <7.0% (preprandial capillary glucose 80-130 mg/dL, 1-2h postprandial <180 mg/dL); stringent targets (<6.5%) apply to younger patients with long life expectancy and low hypoglycemia risk, whereas relaxed targets (<8.0% to <8.5%) are mandated for patients with limited life expectancy, advanced cardiovascular or microvascular disease, extensive comorbidities, or severe hypoglycemic unawareness.

The ADA 2024 goal-directed pharmacotherapy paradigm mandates comorbidity-driven drug selection REGARDLESS of baseline HbA1c or metformin use: patients with established ASCVD or high ASCVD risk require a GLP-1 RA or SGLT2i with proven CV benefit; patients with heart failure (HFrEF or HFpEF) require an SGLT2i; patients with CKD (eGFR 20-60 mL/min or UACR >=30 mg/g) require an SGLT2i and/or non-steroidal MRA finerenone; when weight loss is paramount, tirzepatide (dual GIP/GLP-1 RA) or semaglutide offers the highest efficacy.

Metformin remains the foundational oral agent (titrated to 2000-2550 mg/day; monitor annual vitamin B12; contraindicated if eGFR <30 mL/min/1.73m2; do not initiate if eGFR 30-44); GLP-1 RAs carry boxed warnings for medullary thyroid carcinoma and MEN 2; SGLT2 inhibitors carry risks of euglycemic DKA (hold 3-4 days prior to surgery), mycotic genital infections, and Fournier gangrene; TZDs (pioglitazone) are contraindicated in NYHA Class III/IV heart failure.

Last updated: September 2026

Diagnostic Criteria & Classification of Dysglycemia

Diabetes mellitus represents a group of metabolic disorders characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The American Diabetes Association (ADA) Standards of Care establish clear diagnostic thresholds based on plasma glucose concentrations and glycated hemoglobin (HbA1c).

Diagnostic Thresholds for Dysglycemia ADA DIAGNOSTIC CRITERIA FOR DIABETES AND PREDIABETES

Diagnostic Modality Normal Prediabetes Diabetes Mellitus
═════════════════════════════════════════════════════════════════════════════════════════════════════════
Fasting Plasma Glucose (FPG) < 100 mg/dL 100 to 125 mg/dL >= 126 mg/dL (7.0 mmol/L)
(no caloric intake >= 8 hr) (< 5.6 mmol/L) (Impaired Fasting Glucose) (on 2 occasions)

2-Hour 75g Oral Glucose < 140 mg/dL 140 to 199 mg/dL >= 200 mg/dL (11.1 mmol/L)
Tolerance Test (OGTT) (< 7.8 mmol/L) (Impaired Glucose Tolerance) (on 2 occasions)

Glycated Hemoglobin (HbA1c) < 5.7% 5.7% to 6.4% >= 6.5% (48 mmol/mol)
(NGSP-certified assay) (< 39 mmol/mol) (39 to 47 mmol/mol) (on 2 occasions)

Random Plasma Glucose -- -- >= 200 mg/dL (11.1 mmol/L)
+ Classic Symptoms PLUS classic symptoms*
═════════════════════════════════════════════════════════════════════════════════════════════════════════

*Classic symptoms include polyuria, polydipsia, polyphagia, unexplained weight loss, or hyperglycemic crisis.

The Diagnostic Confirmation Rule

Symptomatic Patients : In an individual presenting with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unintentional weight loss) or unequivocal hyperglycemic crisis (diabetic ketoacidosis or hyperosmolar hyperglycemic state), a single random plasma glucose >=200 mg/dL (11.1 mmol/L) is sufficient to establish the diagnosis of diabetes mellitus without confirmatory re-testing.

Asymptomatic Patients : In the absence of unequivocal symptomatic hyperglycemia, diagnostic confirmation requires two abnormal test results :

Two separate test modalities from the same blood draw (e.g., fasting plasma glucose >=126 mg/dL AND HbA1c >=6.5% drawn simultaneously), OR

Two abnormal results of the same or different test modality performed on two separate days (e.g., FPG >=126 mg/dL repeated on a subsequent visit).

Discordant Test Results : If a patient has two different tests (e.g., FPG and HbA1c) and only one meets the diagnostic threshold, the test that is abnormal must be repeated on a subsequent day. The diagnosis is confirmed if the repeat test remains above the diagnostic threshold.

Prediabetes & Prevention of Type 2 Diabetes

Prediabetes identifies individuals at high risk for future development of type 2 diabetes and cardiovascular disease. Interventions proven to alter this trajectory include:

Intensive Lifestyle Modification : The landmark Diabetes Prevention Program (DPP) demonstrated that an intensive behavioral lifestyle intervention achieving >=7% loss of initial body weight and engaging in >=150 minutes per week of moderate-intensity physical activity (such as brisk walking) reduced the 3-year incidence of type 2 diabetes by 58% overall (and by 71% in adults aged >=60 years ), significantly outperforming pharmacotherapy.

Metformin Pharmacotherapy in Prediabetes : The DPP demonstrated that metformin (850 mg twice daily) reduced diabetes incidence by 31% . ADA guidelines recommend considering metformin therapy in prediabetic individuals, particularly those with:

Body Mass Index (BMI) >=35 kg/m2
Age <60 years
History of gestational diabetes mellitus (GDM)
Progressively rising HbA1c despite intensive lifestyle interventions
Critical Confounders of Glycated Hemoglobin (HbA1c)

HbA1c reflects the non-enzymatic glycation of the N-terminal valine of the hemoglobin beta-chain over the preceding 90 to 120-day lifespan of circulating erythrocytes. Any clinical condition that alters erythrocyte turnover invalidates HbA1c reliability:

Falsely Decreased HbA1c (underestimates true glycemia):

Shortened erythrocyte survival: Hemolytic anemias (autoimmune, hereditary spherocytosis, G6PD deficiency), splenomegaly.

Increased red blood cell turnover: Acute blood loss, recent blood transfusions, treatment with erythropoietin-stimulating agents (ESAs), iron/B12/folate repletion therapy.

End-stage renal disease (ESRD) and chronic hemodialysis.

Pregnancy (second and third trimesters, due to increased RBC turnover and hemodilution; GDM screening requires oral glucose tolerance testing, NOT HbA1c).

Falsely Elevated HbA1c (overestimates true glycemia):

Prolonged erythrocyte survival: Severe iron deficiency anemia, untreated vitamin B12 or folate deficiency anemia, asplenia.

High concentrations of carbamylated hemoglobin in severe uremia.

Hemoglobin Variants (Hemoglobinopathies) : Heterozygous hemoglobin variants (HbS trait, HbC trait, HbE trait) can cause spurious assay interference depending on the analytical method. In patients with homozygous hemoglobinopathies (HbSS, HbCC) or severe RBC turnover alterations, HbA1c must be avoided entirely; glycemic surveillance must rely exclusively on fasting plasma glucose, oral glucose tolerance testing, or continuous glucose monitoring (CGM) metrics.

Individualized Glycemic Targets: De-escalation vs. Stringency

The American Diabetes Association and the European Association for the Study of Diabetes (EASD) emphasize that glycemic targets should not be one-size-fits-all, but must be personalized based on a balance between microvascular risk reduction and hypoglycemia vulnerability. GLYCEMIC TARGET STRATIFICATION ACROSS PATIENT POPULATIONS

Target Level Target HbA1c Patient Characteristics & Clinical Rationale
═════════════════════════════════════════════════════════════════════════════════════════════════════
Stringent Target < 6.5% • Short diabetes duration / newly diagnosed
(< 48 mmol/mol) • Young physiological age with long life expectancy (> 20-30 years)
No significant cardiovascular disease or advanced microvascular disease
Treated with lifestyle or agents with negligible hypoglycemia risk
High cognitive capacity and comprehensive self-management support

Standard Adult < 7.0% • Non-pregnant adults with reasonable life expectancy
Target (< 53 mmol/mol) • Preprandial capillary glucose: 80 to 130 mg/dL (4.4-7.2 mmol/L)
Peak postprandial capillary glucose (1-2 hr): < 180 mg/dL (< 10.0 mmol/L)
Balances microvascular protection with treatment burden

Relaxed / < 8.0% • Older adults with moderate comorbidities and functional impairments
De-escalated (< 64 mmol/mol) • History of severe hypoglycemia or documented hypoglycemic unawareness
Target • Advanced microvascular disease (e.g., CKD Stage 4, severe retinopathy)
Established macrovascular disease (severe CAD, peripheral artery disease)
Longstanding diabetes difficult to control despite multi-drug regimens

Frail / Complex < 8.5% • Limited life expectancy (< 5 years) or end-stage chronic illnesses
Target (< 69 mmol/mol) • Advanced cognitive impairment, moderate-to-severe dementia
Nursing home residents / end-stage palliative or hospice care
Primary clinical goal: Avoid symptomatic hyperglycemia, dehydration,
hyperosmolar crises, and acute symptomatic hypoglycemia
═════════════════════════════════════════════════════════════════════════════════════════════════════

Important

THE ACCORD TRIAL LESSON: THE DANGERS OF OVERTREATMENT The landmark ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial evaluated whether aggressively lowering HbA1c to <6.0% using multi-agent intensive pharmacotherapy reduced cardiovascular events in high-risk patients with longstanding type 2 diabetes. The intensive arm was terminated early due to a significant 22% increase in all-cause mortality driven largely by fatal severe hypoglycemia and cardiovascular collapse. Aggressive tight control must NEVER be pursued in older patients with established cardiovascular disease or severe hypoglycemic risk.

ADA 2024 Goal-Directed Pharmacotherapy Framework

The management of type 2 diabetes has evolved from a glucose-centric strategy to a comprehensive, organ-protective, comorbidity-driven paradigm . While lifestyle intervention and metformin remain foundational, the decision to initiate disease-modifying agents is dictated by specific compelling clinical comorbidities, independent of the patient's baseline HbA1c or current metformin use . ADA 2024 COMORBIDITY-DRIVEN PHARMACOTHERAPY MATRIX

Compelling Comorbidity Mandated First-Line Pharmacotherapy Proven Clinical Trials / Benefit
═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Established ASCVD or GLP-1 Receptor Agonist with proven CV benefit • SUSTAIN-6 (Semaglutide)
High Risk for ASCVD (Subcutaneous Semaglutide, Liraglutide, • LEADER (Liraglutide)
(Age >= 55 with >= 2 risks: Dulaglutide) • REWIND (Dulaglutide)
HTN, dyslipidemia, smoking, OR Reduces 3-point MACE (CV death,
obesity, or albuminuria) SGLT2 Inhibitor with proven CV benefit nonfatal MI, nonfatal stroke)
(Empagliflozin, Dapagliflozin, Canagliflozin) • EMPA-REG, DECLARE, CANVAS
─────────────────────────────────────────────────────────────────────────────────────────────────────────
Heart Failure SGLT2 Inhibitor is MANDATORY • DAPA-HF, DELIVER (Dapagliflozin)
(HFrEF: LVEF <= 40% (Dapagliflozin, Empagliflozin, Sotagliflozin) • EMPEROR-Reduced, EMPEROR-Preserved
OR HFpEF: LVEF > 40%) Initiate regardless of baseline HbA1c Reduces HF hospitalizations & CV death
or concurrent metformin use across the ENTIRE spectrum of LVEF
─────────────────────────────────────────────────────────────────────────────────────────────────────────
Chronic Kidney Disease First-Line: SGLT2 Inhibitor • DAPA-CKD (Dapagliflozin)
(CKD with eGFR 20-60 mL/min (Empagliflozin, Dapagliflozin, Canagliflozin) • EMPA-KIDNEY (Empagliflozin)
OR UACR >= 30 mg/g, Initiate if eGFR >= 20; continue until dial. • CREDENCE (Canagliflozin)
especially > 300 mg/g) Reduces CKD progression & ESRD
Plus Non-Steroidal MRA Finerenone • FIDELIO-DKD, FIGARO-DKD
if eGFR >= 25, K+ <= 4.8, & UACR >= 30 mg/g Reduces cardiorenal events
─────────────────────────────────────────────────────────────────────────────────────────────────────────
Weight Loss as Primary Dual GIP/GLP-1 RA Tirzepatide (Very High) • SURPASS / SURMOUNT (15-20.9% loss)
Therapeutic Goal GLP-1 RA Semaglutide (Very High) • STEP (10-15% loss)
GLP-1 RA Dulaglutide / Liraglutide (High) • Sustained metabolic optimization
SGLT2 Inhibitors (Intermediate: 2-3 kg loss) • Caloric loss via glucosuria
═════════════════════════════════════════════════════════════════════════════════════════════════════════
Step 1: Foundational Lifestyle Modification & Metformin

Lifestyle Foundation : Comprehensive medical nutrition therapy (Mediterranean, low-carbohydrate, or DASH dietary patterns), 150 minutes/week of moderate-intensity aerobic exercise, resistance training 2 to 3 times weekly, smoking cessation, and adequate sleep (7-8 hours nightly).

Metformin (Biguanide) :

Mechanism of Action : Activates AMP-activated protein kinase (AMPK) and inhibits mitochondrial glycerol-3-phosphate dehydrogenase (mGPD) and complex I of the respiratory electron transport chain. This selectively suppresses hepatic gluconeogenesis and glycogenolysis while mildly improving insulin-mediated peripheral glucose disposal in skeletal muscle.

Clinical Profile : Robust HbA1c reduction (1.0% to 1.5%), weight neutrality or modest weight reduction (1-3 kg), virtually zero risk of hypoglycemia as monotherapy, long-term cardiovascular safety track record, and low generic cost.

Dosing : Start at 500 mg orally once daily with the largest meal; titrate weekly by 500 mg to a target maintenance dose of 1000 mg twice daily (or 2000 mg once daily using extended-release [ER] formulations; maximum effective dose is 2550 mg/day).

Metformin Renal Safety Thresholds & Adverse Effects METFORMIN RENAL DOSING ALGORITHM (eGFR-BASED)

eGFR (mL/min/1.73m2) Clinical Metformin Action & Monitoring Strategy
═════════════════════════════════════════════════════════════════════════════════════════════════

>= 60 Full dosing permitted (up to 2000-2550 mg daily). Monitor eGFR annually.

45 to 59 Continue full dosing. Monitor renal function every 3 to 6 months.

30 to 44 DO NOT INITIATE de novo. If already established on therapy:

Reduce dose by 50% (maximum 1000 mg daily). Monitor eGFR every 3 months.

< 30 ABSOLUTE CONTRAINDICATION. Discontinue metformin immediately.

═════════════════════════════════════════════════════════════════════════════════════════════════

Adverse Effects & Clinical Pearls :

Gastrointestinal Intolerance : Bloating, abdominal cramps, nausea, and watery diarrhea occur in up to 25-30% of patients. Mitigate by slow dose titration, administering strictly with meals, or switching to extended-release (ER) formulations.

Vitamin B12 Deficiency : Metformin interferes with calcium-dependent ileal membrane absorption of the vitamin B12-intrinsic factor complex, producing biochemical B12 deficiency in 7% to 10% of long-term users. This can induce or exacerbate peripheral neuropathy (frequently misattributed to diabetic neuropathy) or macrocytic anemia. Monitor serum vitamin B12 levels every 1 to 2 years in all patients on long-term metformin.

Lactic Acidosis Risk : Rare (incidence 3 to 10 cases per 100,000 patient-years) but carries a mortality rate approaching 30-50%. Occurs when drug accumulation coincides with impaired lactate clearance or systemic tissue hypoperfusion (septic shock, acute cardiogenic shock, severe hypoxemic respiratory failure, acute hepatic necrosis).

Radiocontrast Protocol : Withhold metformin at the time of or prior to iodinated radiocontrast imaging in patients with eGFR 30 to 60 mL/min/1.73m2, a history of liver disease, alcoholism, or acute heart failure, or in those receiving intra-arterial contrast. Re-evaluate eGFR 48 hours post-procedure; resume metformin only after confirming renal function stability.

Class-by-Class Clinical Pharmacology & Board-Tested Nuances COMPREHENSIVE COMPARATIVE PHARMACOTHERAPY PROFILES

Drug Class & Agents HbA1c Drop Weight Effect Hypoglycemia Renal Dosing & Cutoffs Key Contraindications & Pearls

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

GLP-1 Receptor 1.0 - 2.0% Major Weight Low • Semaglutide/Liraglutide: • Boxed Warning: Medullary Thyroid

Agonists (GLP-1 RA) Loss No dose adjustment needed. Carcinoma & MEN 2.

• Semaglutide (SC/PO) (-4 to -8 kg) • Exenatide: Avoid eGFR <30. • Adverse: Nausea, pancreatitis.

• Liraglutide (SC) • FLOW trial: Semaglutide • Pre-op: Hold 1 wk (delayed

• Dulaglutide (SC) slows CKD progression. gastric emptying / aspiration).

───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Dual GIP / GLP-1 RA 1.5 - 2.5% Extreme Loss Low No formal dose adjustment. • Boxed Warning: MTC and MEN 2.

• Tirzepatide (SC) (-8 to -15 kg) SURPASS data shows renal • Adverse: Nausea, vomiting,

safety down to eGFR 15. diarrhea, cholelithiasis.

SGLT2 Inhibitors 0.6 - 1.0% Moderate Loss Low • Can start down to eGFR 20; • Adverse: Euglycemic DKA (hold
Empagliflozin (-2 to -3 kg) continue until dialysis. 3-4 days pre-op), mycotic

Dapagliflozin • Glycemic efficacy drops infections, Fournier gangrene.

• Canagliflozin with eGFR <45, but cardiorenal • Hemodynamic eGFR dip (3-5 mL)

protection persists! is reversible & expected.

DPP-4 Inhibitors 0.5 - 0.8% Weight Low • Sitagliptin: Reduce dose • Weight neutral, well tolerated.

(Gliptins) Neutral with declining eGFR. • Linagliptin: NO renal adjust.

• Sitagliptin • Linagliptin: NO renal • DO NOT COMBINE WITH GLP-1 RA!

• Linagliptin adjustment required! • Saxagliptin: Increased HF

• Saxagliptin hospitalization risk.

Sulfonylureas 1.0 - 1.5% Weight Gain HIGH • Glipizide: Preferred in • Closes beta-cell K-ATP channels.

Glipizide (+1 to +3 kg) CKD (inactive metabolites). • Glyburide: Contraindicated in
Glimepiride • Glyburide: AVOID in CKD elderly / CKD (severe prolonged

• Glyburide (active metabolites accum). hypoglycemia; Beers criteria).

Thiazolidinediones 0.8 - 1.5% Weight Gain Low No renal adjustment needed. • PPAR-gamma agonist sensitizer.

(TZDs) (+2 to +4 kg) Can use in advanced CKD. • ABSOLUTE CONTRAINDICATION: NYHA

• Pioglitazone Class III/IV Heart Failure.

• Fluid retention, fractures.

GLP-1 Receptor Agonists & Dual GIP/GLP-1 RA Nuances

Mechanism : Incretin mimetics stimulate GLP-1 (and GIP) receptors, augmenting glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, slowing gastric emptying, and enhancing central hypothalamic satiety.

Cardiovascular Protection : Demonstrates significant reduction in 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in patients with established ASCVD or high CV risk.

Boxed Warning : Contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2) due to GLP-1 receptor-mediated stimulation of thyroid C-cell hyperplasia observed in rodent models.

Perioperative Management : Due to profound inhibition of gastric motility, patients on GLP-1 RAs have an increased volume of retained solid gastric contents despite adherence to preoperative fasting guidelines, posing an acute pulmonary aspiration risk during anesthesia induction . Guidelines advise holding weekly GLP-1 RA formulations for 1 week prior to elective surgery , and holding daily formulations on the morning of surgery.

SGLT2 Inhibitor Nuances & The Perils of Euglycemic DKA

Mechanism : Inhibit the sodium-glucose cotransporter 2 in the proximal convoluted tubule, blocking the reabsorption of filtered glucose and sodium. This results in daily urinary excretion of 50 to 100 grams of glucose (caloric deficit of ~200-300 kcal/day) and osmotic diuresis.

Cardiorenal Mechanics : Increased distal delivery of sodium to the macula densa restores tubuloglomerular feedback , inducing afferent arteriolar vasoconstriction . This lowers pathological intraglomerular capillary hypertension, producing a benign, transient, reversible dip in eGFR (~3 to 5 mL/min/1.73m2) upon initiation while halting long-term nephron loss.

Euglycemic Diabetic Ketoacidosis (euDKA) :

Pathophysiology: Massive renal glucose excretion maintains plasma glucose at normal or only mildly elevated levels (<250 mg/dL, often 150-200 mg/dL), masking metabolic decompensation. Concurrently, glucosuria reduces circulating insulin levels, while glucagon secretion surges. The low insulin-to-glucagon ratio stimulates intense adipose lipolysis and hepatic free fatty acid oxidation, driving runaway ketogenesis (beta-hydroxybutyrate accumulation) and profound high anion gap metabolic acidosis.

Precipitants: Perioperative fasting/stress, acute bacterial/viral sepsis, sudden reduction in exogenous insulin, prolonged intense athletic exertion, low-carbohydrate/ketogenic diets, and heavy alcohol intake.

Perioperative Protocol : SGLT2 inhibitors MUST be held for at least 3 to 4 days prior to any elective surgical procedure (3 days for empagliflozin, dapagliflozin; 4 days for ertugliflozin) or planned major endurance event, and restarted only when oral intake is fully normalized.

Other Adverse Effects : Mycotic vulvovaginitis and candida balanitis (5-10%; treat with topical or oral antifungals without drug cessation), volume depletion/orthostasis, and Fournier Gangrene (a rare, rapidly progressive necrotizing fasciitis of the perineal, genital, or perianal tissue requiring immediate broad-spectrum parenteral antibiotics and emergent surgical debridement).

Sulfonylureas: Avoiding Beers Criteria Traps

Mechanism : Bind the sulfonylurea receptor 1 (SUR1) subunit of the pancreatic beta-cell ATP-sensitive potassium channel (K-ATP), forcing channel closure, cell membrane depolarization, calcium influx, and glucose-independent insulin exocytosis .

Renal Selection Rule : Glyburide is metabolized into active metabolites that depend entirely on renal elimination. In patients with CKD or elderly individuals with declining GFR, glyburide accumulates, causing protracted, life-threatening, refractory hypoglycemia. Glyburide is on the AGS Beers Criteria list of medications to avoid in older adults. Glipizide is metabolized exclusively by the liver into completely inactive metabolites; it is the only preferred sulfonylurea in chronic kidney disease .

Thiazolidinediones (TZDs): Pioglitazone

Mechanism : Selective agonists for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Modulates gene transcription in adipose tissue, skeletal muscle, and liver, enhancing peripheral insulin-mediated glucose uptake.

Heart Failure Contraindication : PPAR-gamma activation upregulates epithelial sodium channels (ENaC) in the renal collecting duct, causing marked sodium and water reabsorption and plasma volume expansion. Pioglitazone is strictly contraindicated in patients with NYHA Class III or IV heart failure and causes peripheral edema and congestive exacerbations.

Skeletal Risk : Diverts bone marrow mesenchymal stem cells away from the osteoblast lineage and toward the adipocyte lineage, decreasing bone mineral density and significantly increasing the incidence of distal extremity bone fractures in postmenopausal women.